BESIFOVIR

NC1=NC=C2N=CN(CC3(CC3)OCP(O)(O)=O)C2=N1

InChIKey=KDNSSKPZBDNJDF-UHFFFAOYSA-N

InChI=1S/C10H14N5O4P/c11-9-12-3-7-8(14-9)15(5-13-7)4-10(1-2-10)19-6-20(16,17)18/h3,5H,1-2,4,6H2,(H2,11,12,14)(H2,16,17,18)

Besifovir (also known as LB80331), an active metabolite of LB80380 was studied for the treatment of hepatitis B.

PubMed

Title	Date	PubMed
A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent.	2004 May 20	15139764
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease.	2010 Mar	20091678
Pharmacokinetic comparison of the maleate and free base formulations of LB80380, a novel nucleotide analog, in healthy male volunteers.	2012 Sep	22981147
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.	2014 Jun	23979965

Patents

In Vivo Use Guide

Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.

Route of Administration: Oral

Name

Type

Language

BESIFOVIR

Official Name

English

(((1-((2-AMINO-9H-PURIN-9-YL)METHYL)CYCLOPROPYL)OXY)METHYL)PHOSPHONIC ACID

Systematic Name

English

besifovir [INN]

Common Name

English

PHOSPHONIC ACID, P-(((1-((2-AMINO-9H-PURIN-9-YL)METHYL)CYCLOPROPYL)OXY)METHYL)-

Common Name

English

Besifovir [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

5270766